Discovery of a putative blood-based protein signature associated with response to ALK tyrosine kinase inhibition

BACKGROUND: ALK tyrosine kinase inhibition has become a mainstay in the clinical management of ALK fusion positive NSCLC patients. Although ALK mutations can reliably predict the likelihood of response to ALK tyrosine kinase inhibitors (TKIs) such as crizotinib, they cannot reliably predict response...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Proteomics
Main Authors: Couëtoux du Tertre, Mathilde, Marques, Maud, McNamara, Suzan, Gambaro, Karen, Hoffert, Cyrla, Tremblay, Lise, Bouchard, Nicole, Diaconescu, Razvan, Blais, Normand, Couture, Christian, Pelsser, Vincent, Wang, Hangjun, McIntosh, Laura, Hindie, Valérie, Parent, Stephane, Cortes, Laetitia, Breton, Yannick-André, Pottiez, Gwenael, Croteau, Pascal, Higenell, Valerie, Izzi, Luisa, Spatz, Alan, Cohen, Victor, Batist, Gerald, Agulnik, Jason
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2020
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7006423/
https://ncbi.nlm.nih.gov/pubmed/32055239
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12014-020-9269-6
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados